- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
New York will soon host a $100 million fund for life sciences research along with a new institute focusing on medical technology, Crain’s New York Business reported.
New York will soon host a $100 million fund for life sciences research along with a new institute focusing on medical technology, Crain’s New York Business reported.
As quoted in the market news:
During a press conference at Rockefeller University, [Deputy Mayor Robert] Steel unveiled the City of New York Early-Stage Life Sciences Funding Initiative, a public-private effort that will be seeded by $10 million from the city Economic Development Corp. and $40 million from corporate sponsors Celgene, GE Ventures and Eli Lilly & Co. That $50 million is expected to be matched through venture capital partnerships, creating a $100 million fund to be administered across the city’s life science-focused research universities, which will aim to initiate 15 to 20 early-stage research and development ventures by 2020.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.